Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The current list price for Ozempic is $997.58 per pen without insurance. While this drug can be expensive, Novo Nordisk offers a savings card for those with commercial or private insurance who are ...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Weight-loss drugs are increasingly popular among employees but weigh heavily on health-insurance budgets. Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor in ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.